in San Mateo, Calif., which will bulk ship kits to collect nasal swab samples that can processed within 24 to 48 hours through a combination of automation and "next-generation sequencing," which has been used in research to scan genomes. In this case, it's being used to spot the genetic material of the coronavirus. This technology, best known for editing DNA, can zero in on any spot in a genetic code. Mammoth Biosciences, Inc., in San Francisco., which uses CRISPR. The seven companies receiving grants are: And dozens of others are also still under consideration More then 20 others are still under consideration for Phase 2. "These have now reached the point where we think it's time to go big," Collins said. The seven announced Friday are the first selected to move on Phase 2 of the program, which will involve scaling them up and manufacturing them for use, the NIH says. Thirty-one then progressed through a four- to six-week Phase 1 evaluation. About 100 of those went through a one-week "shark tank" evaluation. The RADx program has received more than 650 applications so far, according to the NIH. "It will be interesting to see how this plays out, and if supply can ever catch up with the soaring demand," Green wrote in an email to NPR. One of the tests is already on the market and others "may not always be as sensitive" as those already in use, according to Daniel Green, an assistant professor of pathology & cell biology at Columbia University. While the first winners appear promising, some observers remain cautious. Procop chairs the Commission of Science, Technology and Policy for the American Society for Clinical Pathology. "All of the products identified through the NIH's RADx program are exciting in their own right, and I anticipate many will find a place in the market to expand our testing capabilities and help in the fight against COVID-19," he wrote in an email. Gary Procop, a professor of pathology at the Cleveland Clinic was also upbeat about the announcement.
"The big question is how quickly can these technologies be scaled up and made available on the front lines. "It's pretty exciting," said Ashish Jha, who runs the Harvard Global Health Institute, via an email to NPR. Public health and testing researchers welcomed the new technologies. The hope is that new tests could allow students, teachers and other workers to get tested frequently to help beat back the pandemic and safely reopen the nation. A third uses a hand-held device that produces results within 30 minutes.Ĭongress gave the NIH $1.5 billion in the spring to jump-start the hunt for technologies that would enable millions of Americans to get easier access to faster, cheaper, accurate tests.
Another uses a technique for scanning the genetic code to see if someone is infected. One test uses the revolutionary gene-editing technique called CRISPR to spot the coronavirus.
Internal applications, then our B2B based Bizapedia Pro API™ might be the answer for you."This is a very substantial investment to try to speed up the availability of COVID-19 testing to try to deal with this pandemic," NIH Director Francis Collins told reporters during a telebriefing. If you are looking for something more than a web based search utility and need to automate company and officer searches from within your WHAT'S INCLUDED IN THE ADVANCED SEARCH FORM? Utilize our advanced search form to filter the search results by Company Name, City, State, Postal Code, Filing Jurisdiction, Entity Type, Registered Agent,įile Number, Filing Status, and Business Category.
While logged in and authenticated, you will not be asked to solve any complicated Recaptcha V2 challenges. In addition, all pages on Bizapedia will be served to you completely ad freeĪnd you will be granted access to view every profile in its entirety, even if the company chooses to hide the private information on their profile from the general public. Your entire office will be able to use your search subscription.